Logo

LIXT

Lixte Biotechnology Holdings, Inc.

LIXT

Lixte Biotechnology Holdings, Inc. • NASDAQ
$4.27 ▲ 1.43% (+0.06)
Market Cap $19.43 M
52w High $6.26
52w Low $0.64
Dividend Yield 0%
P/E -3.59
Volume 74.40K
Outstanding Shares 4.55M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.801M ▲ $-2.031M ▼ 0% $-0.33 ▼ $-2.03M ▼
Q2-2025 $0 $774.809K ▲ $-775.673K ▼ 0% $-0.29 $-773.863K ▼
Q1-2025 $0 $706.94K ▲ $-709.555K ▼ 0% $-0.29 ▼ $520 ▲
Q4-2024 $0 $613.497K ▼ $-617.694K ▲ 0% $-0.27 ▲ $0 ▲
Q3-2024 $0 $983.257K $-986.03K 0% $-0.44 $-984.981K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.342M ▲ $5.434M ▲ $521.422K ▼ $4.912M ▲
Q2-2025 $887.212K ▼ $1.189M ▼ $537.122K ▲ $651.456K ▼
Q1-2025 $1.385M ▲ $1.514M ▲ $355.098K ▲ $1.159M ▲
Q4-2024 $1.039M ▼ $1.146M ▼ $318.284K ▼ $827.219K ▼
Q3-2024 $1.638M $1.696M $328.956K $1.367M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.98M ▼ $-926.752K ▼ $-2.637M ▼ $5.565M ▲ $2.001M ▲ $-926.75K ▼
Q2-2025 $-775.673K ▼ $-487.485K ▲ $0 $-10K ▼ $-497.485K ▼ $-487.48K ▲
Q1-2025 $-709.555K ▼ $-568.483K ▲ $0 $914.228K ▲ $345.745K ▲ $-568.48K ▲
Q4-2024 $-617.694K ▲ $-598.675K ▲ $0 $0 $-598.675K ▲ $-598.675K ▲
Q3-2024 $-986.03K $-957.595K $0 $0 $-957.595K $-957.6K

Five-Year Company Overview

Income Statement

Income Statement Lixte is still a classic early‑stage biotech: it has essentially no product revenue and has reported losses every year. Earnings per share have been negative and fairly large in absolute terms, which mainly reflects R&D and operating costs spread over a small company base, not any underlying commercial weakness. The key point is that the business is entirely in the development phase, with expenses but no sales yet, so profitability is not a near‑term feature of the story.

Balance Sheet

Balance Sheet The balance sheet is very light, with only modest assets and no reported financial debt. That means relatively little leverage risk, but also a limited financial cushion. Equity is small, which is typical for a micro‑cap biotech that has funded itself through periodic equity raises. The history of reverse stock splits also hints at past pressure on the share price and a need to preserve listing status, underlining the fragile capital structure.

Cash Flow

Cash Flow Operating and free cash flow are effectively negative once you look past the rounded figures: the company spends cash on R&D and overhead while bringing in no operating revenue. With no meaningful internal cash generation, the business is reliant on external financing—typically equity offerings or partnerships—to fund clinical trials and now, potentially, radiotherapy commercialization. Cash management and access to capital will remain critical swing factors.

Competitive Edge

Competitive Edge Competitively, Lixte is trying to differentiate itself with a first‑in‑class PP2A inhibitor (LB‑100) and a proprietary proton therapy platform (LiGHT). The drug candidate aims to make existing chemo, immunotherapy, and radiation work better rather than competing directly against them, which is a distinctive angle. Collaboration with large pharma and leading cancer centers adds scientific credibility, but the company is still very small relative to oncology giants, so execution, partnerships, and trial results will largely determine how durable its competitive edge becomes.

Innovation and R&D

Innovation and R&D Innovation is the core of Lixte’s story. LB‑100 targets a novel cancer pathway with a mechanism designed to "sensitize" tumors, and the company is running multiple early‑ to mid‑stage trials in difficult‑to‑treat cancers. On top of that, acquiring the LiGHT proton therapy system puts Lixte at the intersection of advanced drugs and advanced radiation hardware—an unusually broad R&D scope for a company of this size. This creates intriguing scientific and commercial possibilities but also increases complexity, cost, and execution risk.

Summary

Overall, Lixte is an early‑stage, high‑risk oncology platform with no current revenue, ongoing losses, and a very lean balance sheet, fully dependent on external capital. Its appeal rests almost entirely on the promise of its science: a first‑in‑class PP2A inhibitor and a potentially lower‑cost, high‑precision proton therapy system. The next few years will likely hinge on clinical trial readouts, regulatory progress, and the company’s ability to turn its technology portfolio into real‑world partnerships and eventually commercial use, all while carefully managing its limited financial resources.

NEWS

November 25, 2025 · 8:30 AM UTC

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

Read more

October 29, 2025 · 8:00 AM UTC

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Read more

October 16, 2025 · 8:00 AM UTC

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Read more

September 16, 2025 · 8:30 AM UTC

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

Read more

September 15, 2025 · 5:40 PM UTC

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

Read more